Physician profile
Christopher Kim
NPI 1538696117
$9,381.62
in general payments reported to CMS, 2019-2025
24 companies · $2,776 in 2025
The $2,776 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $2,367 · 2023: $1,101 · 2024: $2,891 · 2025: $2,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,591 · Travel and Lodging: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,590.91 |
| Travel and Lodging | $1,176.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,923.81 | 2021-2025 | |
| Wilson Cook Medical Incorporated | $1,873.36 | 2022-2025 | Hemospray |
| Regeneron Healthcare Solutions, INC. | $805.54 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $796.40 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Medtronic, INC. | $681.91 | 2024 | |
| Genzyme Corporation | $635.48 | 2023-2025 | |
| Boston Scientific Corporation | $422.80 | 2021-2025 | Exalt Model D, General - Metal Stents - G.I., Habib Endohpb |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.54 | 2021-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $390.01 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $318.85 | 2023-2024 | Zeposia |
| Amgen INC. | $286.08 | 2023 | Repatha |
| Madrigal Pharmaceuticals | $165.16 | 2025 | Rezdiffra |
| Conmed Corporation | $153.46 | 2025 | Conmed Generators, Conmed Dilation |
| Gilead Sciences, INC. | $139.36 | 2023 | Epclusa |
| Lilly USA, LLC | $105.17 | 2024-2025 | Omvoh |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $61.17 | 2024-2025 | Tremfya |
| Celltrion USA INC. | $53.90 | 2024-2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $41.08 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $33.16 | 2023-2024 | Dificid |
| Alcresta Therapeutics, INC. | $24.48 | 2023 | Relizorb |
| Ironwood Pharmaceuticals, INC | $22.58 | 2022 | |
| Ardelyx, INC. | $18.55 | 2025 | Ibsrela |
| Novo Nordisk INC | $16.15 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $15.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.